AP Biosciences, Inc. (TPEX:6945)

Market Cap	11.90B +37.1%
Revenue (ttm)	n/a
Net Income	-464.34M
EPS	-5.38
Shares Out	97.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	133,432
Open	122.50
Previous Close	122.00
Day's Range	121.00 - 123.50
52-Week Range	86.10 - 236.00
Beta	-0.45
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 22, 2026

About AP Biosciences

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 37
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6945

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error